medline.ch Onkologie

	(177)Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer. Radiology Ayati N, Papa N, Crumbaker M, Subramaniam S, Joshua AM, Alipour R, Iravani A, Askari E, Khan S, Yadav S, Eiber M, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Nguyen A, Hofman MS, Sandhu S, Hioki T, van Oorschodt JCJ, Devitt K, Willowson K, Sharma S, Stancu A, Chauvie S, Wilson P, Martin AJ, Thomas H, Stockler MR, Davis ID, Emmett L, Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. PMID: 42048586 [PubMed - indexed for MEDLINE]
	CD38 genotype-dependent regulation of CD44 and TP53 links genetic variation to aggressive phenotype in chronic lymphocytic leukemia. Pol Merkur Lekarski Hussain MA, Amer ME, El-Ashwah S, ElKosairy M, El-Sherbini YM, Mabed M, Abdraboh ME. PMID: 42048498 [PubMed - indexed for MEDLINE]
	Participation in Cervical and Breast Cancer Screening Among Working Women in Japan: Panel Survey Study. JMIR Cancer Satoh M, Sato N. PMID: 42048492 [PubMed - indexed for MEDLINE]
	A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer. Clin Cancer Res Akay M, Glendenning J, Tovey H, Tsai YT, Graham R, Carpenter E, Kakkassery H, Alaguthurai T, Finneran L, Roxanis I, Swampillai A, Harries M, Sandri I, Karthigan R, Barrington S, Gazinska P, Cook G, Chicklore S, Bliss J, Haider S, Tutt A, Irshad S. PMID: 42048392 [PubMed - as supplied by publisher]
	Comparative study of ocular and generalized myasthenia gravis in a South Korean cohort. PLoS One Kwon C, Oh J, Shin HJ. PMID: 42048329 [PubMed - indexed for MEDLINE]
	Retraction: High CASC expression predicts poor prognosis of lung cancer: A systematic review with meta-analysis. PLoS One PLOS One Editors. PMID: 42048307 [PubMed - in process]
	Measurement of CYFRA 21-1 in Fine-Needle Washout of Cervical Lymph Nodes in Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Acta Cytol Garo ML, Bongiovanni M, De Virgilio A, Giovanella L. PMID: 42048293 [PubMed - as supplied by publisher]
	Subsequent primary cancer incidence among cancer survivors in the United States, 1975-2019: An age-period-cohort analysis. PLoS Med Cheng HG, Aduse-Poku L, McGill C, Palesh O, Hong S. PMID: 42048284 [PubMed - indexed for MEDLINE]
	Routine Retrograde Conduitography after Radical Cystectomy for Bladder Cancer: Diagnostic Yield and Clinical Impact. Urol Int Scheper V, Berninger L, Schwinger M, Woidich R, Egenolf T, Däuwel M, Hahn O, Seitz AK, Kübler H, Kalogirou C. PMID: 42048277 [PubMed - as supplied by publisher]
	Interval appendicectomy after conservative management of complicated appendicitis: Balancing recurrence, neoplasm risk, and surveillance strategies. Dig Surg Gosavi R, McMurrick P, Teoh W, Ooi G, Narasimhan V. PMID: 42048268 [PubMed - as supplied by publisher]
	Clinical Significance of Biomarkers in Oropharyngeal Squamous Cell Carcinoma: Recurrence Prediction and Treatment Response. Cancer Rep (Hoboken) Chen Y, Zhang W, Gao X, Xing K, Ren Y, Hu J, Xie Z, Zhou P. PMID: 42048145 [PubMed - indexed for MEDLINE]
	Reduction in ELOVL2 methylation following curative surgery in lung cancer patients: an observational study. Epigenomics Li P, Chen Z, Zhang X, Zeng C, Chen Y, Yang S, Xiong Y. PMID: 42048074 [PubMed - as supplied by publisher]
	First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590. Esophagus Kato K, Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Yatsuzuka N, Sakata T, Han S, Doi T. PMID: 42047965 [PubMed - as supplied by publisher]
	Histone mark remodeling in cancer: an enhancer-centered perspective. Genes Genomics Park J, Jeon J, Gim S, Chung C. PMID: 42047907 [PubMed - as supplied by publisher]
	The Role of Molecular Testing in Head and Neck Squamous Cell Carcinoma of Unknown Primary. Head Neck Pathol Yasin I, Hang JF, Chu YH. PMID: 42047904 [PubMed - in process]
	Metformin in prostate cancer: a context-dependent antitumour strategy driven by metabolic vulnerability and signalling network. Discov Oncol Yan L, Chen D, Wu T, Zhao J, Xu X, Xu W, Zhang H, Xiao M. PMID: 42047898 [PubMed - as supplied by publisher]
	Impact of baseline nutritional and inflammatory markers on safety and efficacy of immune checkpoint inhibitors in cancer patients: a retrospective, monocentric study. Discov Oncol Baggi A, Smussi D, Lorini L, Stucchi E, Zamparini M, Bettini DL, Alessandrini N, Capelli C, Azzolini J, Tovazzi V, Consoli F, Volta AD, Valcamonico F, Grisanti S, Berruti A, Bossi P. PMID: 42047890 [PubMed - as supplied by publisher]
	Formulation of treatment protocol for ocular surface squamous neoplasia. Int Ophthalmol Daryabari SH, Aghamollaei H, Hassanpour SR, Rezaei J, Hosseini Imeni SM, Sepandi M, Raei M. PMID: 42047870 [PubMed - indexed for MEDLINE]
	AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma. Cancer Immunol Immunother Ren Z, Huang Y, Guo Y, Hou MM, Wang W, Kuang M, Hao C, Wang W, Zhang Y, Song T, Dai C, Kuo HT, Bao Z, Zuo Y, Wang L, Zhu F, Fan J. PMID: 42047833 [PubMed - indexed for MEDLINE]
	Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy. Cancer Immunol Immunother Gámez-Pozo A, Trilla-Fuertes L, Becerril-Gómez F, Lalanda-Delgado P, Soriano V, Garicano Goldaraz F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez-Ruiz E, González-Cao M, Oramas J, López-Vacas R, Magdaleno A, Fra J, Martín-Carnicero A, Corral M, Puértolas T, Ramos-Ruiz R, Espinosa E, Fresno Vara JÁ. PMID: 42047827 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 1929876

Seite 1 von 96494

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung